Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
510 results about "Chemical toxicity" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Toxicity is the degree to which a chemical substance or a particular mixture of substances can damage an organism.
Therapeutic formulations for the treatment of beta-amyloid related diseases
InactiveUS20050031651A1Impairs daily activityAvoid impairmentPharmaceutical delivery mechanismPharmaceutical active ingredientsCytotoxicityAmyloid
This invention relates to methods and pharmaceutical compositions for treating amyloid-β related diseases, including Alzheimer's disease. The invention, for example, includes a method of concomitant therapeutic treatment of a subject, comprising administering an effective amount of a first agent and a second agent, wherein said first agent treats an amyloid-β disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement.
Owner:BELLUS HEALTH (INT) LTD (CH)
Substrate processing method
ActiveUS20110204025A1Decorative surface effectsPretreated surfacesDecompositionAMMONIUM SILICOFLUORIDE
A silicon-containing film on a substrate is subjected to a plasma process using a process gas containing fluorine and carbon, and is thereafter subjected to plasma process using an ammonia gas, whereby ammonium silicofluoride having toxicity and hygroscopic property is adhered to the substrate. The harmful ammonium silicofluoride is removed by the inventive method. After conducting the plasma process using an ammonia gas, the substrate is heated to a temperature not lower than the decomposition temperature of the ammonium silicofluoride to decompose the ammonium silicofluoride in a process container in which the plasma process was conducted, or in a process container connected with the processing vessel which the plasma process was conducted therein and is isolated from a clean room atmosphere.
Owner:TOKYO ELECTRON LTD
Methods of predicting and monitoring tyrosine kinase inhibitor therapy
InactiveUS20070254295A1Eliminate side effectsCompound screeningApoptosis detectionAbnormal tissue growthSide effect
Owner:SOC DES PROD NESTLE SA
Individualized cancer treatments
InactiveUS20070172844A1Increase probabilityLow toxicityBioreactor/fermenter combinationsBiological substance pretreatmentsDNA microarrayPlatinum
The invention provides for compositions and methods for predicting an individual's responsitivity to cancer treatments and methods of treating cancer. In certain embodiments, the invention provides compositions and methods for predicting an individual's responsitivity to chemotherapeutics, including platinum-based chemotherapeutics, to treat cancers such as ovarian cancer. Furthermore, the invention provides for compositions and methods for predicting an individual's responsivity to salvage therapeutic agents. By predicting if an individual will or will not respond to platinum-based chemotherapeutics, a physician can reduce side effects and toxicity by administering a particular additional salvage therapeutic agent. This type of personalized medical treatment for ovarian cancer allows for more efficient treatment of individuals suffering from ovarian cancer. The invention also provides reagents, such as DNA microarrays, software and computer systems useful for personalizing cancer treatments, and provides methods of conducting a diagnostic business for personalizing cancer treatments.
Owner:UNIV OF SOUTH FLORIDA +1
Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
InactiveUS20110016540A1Vertebrate cellsArtificial cell constructsZinc finger nucleaseChemical toxicity
The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with trinucleotide repeat expansion disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.
Owner:SIGMA ALDRICH CO LLC
Adult stem cells and uses thereof
InactiveUS20050260748A1High expressionHigh activityHepatocytesGenetically modified cellsAdult liverCell culture media
Disclosed are compositions and methods for isolating, immortalizing and differentiating adult stem cells, for example, particular human clonal adult liver stem cells or adipose stem cells, including specialized cell culture media for the isolation and propagation of such stem cells. Also disclosed are methods of screening for toxicity, carcinogenicity and therapeutic activity using such stem cells and immortalized or differentiated derivatives thereof. In addition, methods of treatment using such stem cells and their differentiated or immortalized derivatives thereof are disclosed.
Owner:MICHIGAN STATE UNIV
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
ActiveUS20070077246A1Treating and preventing and ameliorating symptomSlow and reduce damagePeptide/protein ingredientsAntipyreticAutoimmune conditionAutoimmune disease
The present invention provides methods of treating, preventing or ameliorating the symptoms of T cell-mediated immunological diseases, particularly autoimmune diseases, through the use of anti-CD3 antibodies. In particular, the methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor / alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the invention provides for modification of the anti-CD3 antibodies such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-CD3 antibodies.
Owner:PROVENTION BIO INC
Abuse Resistant and Extended Release Formulations and Method of Use Thereof
InactiveUS20090082466A1Reducing solvent extraction efficiencyReduce filtration efficiencyBiocidePharmaceutical non-active ingredientsOpioid abuseChemical toxicity
The present invention is in the field of oral, abuse resistant pharmaceutical compositions of opioids, extended release pharmaceutical compositions of opioids and extended release abuse resistant pharmaceutical compositions of opioids and the use thereof for the treatment of pain. The present invention is also directed to extended release pharmaceutical compositions and the use thereof for preventing or minimizing the risk of opioid abuse and / or opioid toxicity from either intentional or unintentional tampering. The present invention is further directed at a method of preventing or minimizing the risk of opioid abuse and / or opioid toxicity from either intentional or unintentional tampering.
Owner:RELMADA THERAPEUTICS
Medical Devices and Coatings with Non-Leaching Antimicrobial Peptides
InactiveUS20070254006A1Solve the lack of flexibilityPromote adequate mobilityAntibacterial agentsBiocideAntibiotic resistanceFungal microorganisms
Antimicrobial peptides enable an alternate approach to developing antimicrobial coatings due to their targeting of the membranes of the bacteria. High specific activity is achieved by orienting the peptides so that the antimicrobial ends of the peptides maximally contact the bacteria. In one embodiment, one end of the peptide is covalently attached directly to the substrate. In another embodiment, the peptides are immobilized on the substrate using a coupling agent or tether. Non-covalent methods include coating the peptide onto the substrate or physiochemically immobilizing the peptides on the substrate using highly specific interactions, such as the biotin / avidin or streptavidin system. The compositions are substantially non-leaching, antifouling, and non-hemolytic. The immobilized peptides retain sufficient flexibility and mobility to interact with and de endocytosed by the bacteria, viruses, and / or fungi upon exposure. Immobilizing the peptides to the substrate reduces concerns regarding toxicity of the peptides and the development of antimicrobial resistance, while presenting substantially all of the peptide at the site of action at the surface of the substrate.
Owner:MASSACHUSETTS INST OF TECH
Double-stranded rna structures and constructs, and methods for generating and using the same
InactiveUS20060035344A1Improve efficiencyPrevent gene silencingAntibody mimetics/scaffoldsMicrobiological testing/measurementNucleic acid sequencingSilencing gene
The present invention relates to novel double-stranded RNA (dsRNA) structures and dsRNA expression constructs, methods for generating them, and methods of utilizing them for silencing genes. Desirably, these methods specifically inhibit the expression of one or more target genes in a cell of animal (e.g., a mammal such as a human) without inducing toxicity. These methods can be used to prevent or treat a disease or infection by silencing a gene associated with the disease or infection. The invention also provides method for identifying nucleic acid sequences that modulate a detectable phenotype, such as the function of a cell, the expression of a gene, or the biological activity of a target polypeptide.
Owner:ALNYLAM PHARM INC
Topical management of ocular and periocular conditions
Chronic glaucoma, cataract, ocular and periocular aging are treated and prevented by the administration of agents that affect metabolic subsystems such as (i) mitochondrial bioenergetics, (ii) free radical moderation and glutathione maintenance, (iii) constitutive nitric oxide / endothelin-1 balance, and (iv) calcium wave signaling and associated neuronal excito-toxicity. Included among the agents are tetrahydrobiopterin, R-alpha-lipoic acid, coenzyme Q10, 17 alpha-estradiol, and glutathione.
Owner:CHRONORX
Nucleic acid carriers for delivery of therapeutic agents
InactiveUS20070225213A1Improve solubilityLow biological effectHeavy metal active ingredientsBiocideIn vivoProliferation rate
Nucleic acid drug carriers comprise a nucleic acid carrier complexed with a drug, wherein the nucleic acid carrier and the drug are associated non-covalently, and optionally other agents such as spacer, transfection agents, and targeting agents. The nucleic acid drug complex are discovered to have permissive or refractory uptake depending on many factors including cell type, proliferation rate, among others. The refractive uptake of the nucleic acid drug complex are shown to be useful in the nucleic acid targeting of drugs, both in vitro and in vivo. Novel drug compositions are disclosed that effectively reduce the toxicity of drugs while maintaining drug activity and enhancing a drug's therapeutic index.
Owner:KOSAK MATTHEW K
Melphalan prodrugs
InactiveUS20050214310A1High specificity of actionImprove stabilityNanomedicineAntibody ingredientsSolubilityTherapeutic window
Shown and described are the synthesis of more potent forms of C-Mel, a prodrug used in Antibody-Directed Enzyme Prodrug Therapy, that releases the clinically used anticancer alkylating agent melphalan extracellularly. Shown and described are the synthesis of a variety of melphalan analogues with the intention to promote facile intracellular drug access. Esters, amides, and peptides of melphalan are shown. Cephalosporin prodrugs of the most interesting melphalan derivatives were synthesized and evaluated for potency, toxicity, therapeutic window, plasma stability, and solubility.
Owner:SEATTLE GENETICS INC
Method of manufacture and treatment of wood with injectable particulate iron oxide
InactiveUS20060075923A1Reduces UV-promoted degradation of the wood substrateAppearance hasFireproof paintsBiocideParticulatesPreservative
A wood preservative includes injectable particles comprising one or more sparingly soluble iron salts. The iron-based particles are sufficiently insoluble so as to not be easily removed by leaching but are sufficiently soluble to exhibit toxicity to primary organisms primarily responsible for the decay of the wood. Wood or a wood product may be impregnated with iron-based particles of the invention.
Owner:OSMOSE
Inorganic hydrated salt expanded graphite composite phase-changing heat storage material and preparation method thereof
The invention relates to an inorganic hydrated salt expanded graphite composite phase-changing heat storage material. In the preparation method thereof, 85-89 mass parts of inorganic hydrated salt sodium acetate trihydrate as a heat storage matrix, 5.5-6.5 mass parts of disodium hydrogenphosphate as a nucleating agent, 2.5-3.5 mass parts of carboxymethyl cellulose as a thickening agent, and 3-4.5 mass parts of expanded graphite is blended in an inorganic hydrated salt mixture as a material with a high thermal conductivity. Due to the use of the expanded graphite, the material not only maintains excellent properties of natural flake graphite such as good thermal conductivity, no toxicity and the like, but also has adsorbability which the natural flake graphite does not have. The invention solves the problems of sub-cooling degree, phase stratification and low thermal conductivity during the heat storage process. The composite phase-changing material has a low sub-cooling degree after the phase changing performance is improved, the solution thereof is uniform without sedimentation and stratification during the solid-liquid phase change, the performance is stable, the repeatability of good, and the phase-changing heat storage can be enhanced through improving the thermal conductivity of the material.
Owner:ENG COLLEGE OF ENG CORPS PLA UNIV OF SCI & TECH
Methods for the Treatment of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies with Reduced Toxicity
ActiveUS20080095766A1Reduce the possibilityIncreasing concentration of antibodySenses disorderNervous disorderDosing regimenInsulin dependent diabetes
The present invention provides methods of treating, preventing, slowing the progression of, or ameliorating the symptoms of T cell mediated immunological diseases, particularly autoimmune diseases (e.g., autoimmune diabetes (i.e. type 1 diabetes or insulin-dependent diabetes mellitus (IDDM)) and multiple sclerosis) through the use of anti-human CD3 antibodies. The antibodies of the invention of the invention are preferably used in low dose dosing regimens, chronic dosing regimens or regimens that involve redosing after a certain period of time. The methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor / alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the methods of the invention provide for use of anti-human CD3 antibodies modified such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-human CD3 antibodies.
Owner:PROVENTION BIO INC
Acid-cleaning inhibiter for cleaning boiler and use method thereof
ActiveCN101634030ASlow down the dissolution rateIncrease activation energyBoiler cleaning apparatusThioureaPhosphoric acid
The invention discloses an acid-cleaning inhibiter for cleaning a boiler and a use method thereof. The acid-cleaning inhibiter comprises the following components by weight percent: 2.0%-10.0% of acid liquor, 0.08-0.25% of urotropine, 0.04-0.15% of dimethylbenzene thiourea or thiourea, 0.01-0.05% of thiocyanate, 0.03-0.12% of dodecyl-cetyl phenmethyl chloride or bromide, 0.05-0.12% of a surface active agent and the balance of water. Acids suitable for the acid-cleaning inhibiter include hydrochloric acid, citric acid, sulphuric acid, hydrofluoric acid, aminosulfonic acid and phosphoric acid, which are suitable for boiler steel, mild steel, alloy steel and steam steel. The inhibition effect of the invention is over 98% with less toxicity under the boiler chemical cleaning condition, the value of LD50 (orally taken by mice) is 5.74 g / kg. The invention can be stored for 2 years, resistant Fe<3+> ion is 800 mg / kg in the acid cleaning. The preparation method has simple steps, easily obtained raw materials and convention operation.
Owner:湖南省湘电试验研究院有限公司 +2
Ink composition and image process using the same
InactiveUS20060158493A1Measurement apparatus componentsDuplicating/marking methodsUltravioletViscosity
The present invention relates to an ink composition containing a monofunctional monomer at a mixing ratio of 50 to 70% by weight, a bifunctional monomer at a mixing ratio of 10 to 30% by weight and a multifunctional monomer at a mixing ratio of 1 to 10% by weight. According to the invention, there is provided an ultraviolet curing type ink composition which is curable with an ultraviolet ray, high in its curing (polymerization) rate, and low in viscosity and toxicity. Further, an imaging process using the above-mentioned ink composition is also disclosed.
Owner:SEIKO EPSON CORP
Large-Scale Production of Human Serum Butyrylcholinesterase as a Bioscavenger
InactiveUS20070184045A1Treating and preventing and inhibiting toxicityPeptide/protein ingredientsHydrolasesCholinesteraseButyrylcholinesterase
Disclosed herein are methods for the large-scale preparation of human butyrylcholinesterase (HuBChE) preparations from Cohn Fraction IV-4. As disclosed, the methods provide HuBChE preparations that are about 99% or more pure with recovery yields of about 60%. Also disclosed are the pharmacokinetics, safety and toxicity, stability and efficacy of the HuBChE preparations.
Owner:UNITED STATES OF AMERICA THE AS REPRESENTED BY THE SEC OF THE ARMY
Cyclodextrin-based polymers for therapeutics delivery
InactiveUS20060210527A1Improve drug stabilityImprove solubilityNanomedicinePharmaceutical non-active ingredientsPresent methodCyclodextrin
The present invention relates to novel compositions of therapeutic polymeric compounds designed as carriers for small molecule therapeutics delivery and pharmaceutical compositions thereof. In some embodiments, the small molecule therapeutic is attached to the polymer by a photocleavable linker. The polymeric compounds may also employ targeting agents. By selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. On reaching a targeted site in the body of a patient, the linker can then be cleaved by the shining of ultraviolet, visible, or infrared wavelength light onto the site. The methods provide reduced toxicity and local delivery of therapeutics. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.
Owner:CERULEAN PHARMA
Pharmacological agent and method of treatment
InactiveUS20060074063A1Eliminate effectiveEliminate energyBiocideGroup 8/9/10/18 element organic compoundsWhole bodyVirus warts
An antiproliferative, antiinflammatory, antiinfective, immunization agent of a metal ion chelating agent such as picolinic acid, analogs or derivatives thereof, and methods of using the same. The agents chelate metals in metal containing protein complexes and enzymes required for growth, replication or inflammatory response. The preparations can be administered systemically or topically. The products can be used to reduce systemic levels of metals in disease states such as Wilson's disease, iron or lead toxicity. The preparations have antineoplastic, antiviral, antiinflammatory, analgesic antiangiogenic and antiproliferative effects and are used in the treatment of warts, psoriasis, acne, cancers, sunburn, inflammatory responses, untoward angiogenesis and other diseases and in the prevention of sexually transmitted diseases such as genital warts, herpes and AIDS.
Owner:NOVACTYL
Device and method for treatment of wounds with nitric oxide
InactiveUS20050191372A1Promote healingPrevent leakageBiocideOther blood circulation devicesHigh concentrationNitric oxide gas
Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing of the wound and in preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used, for example, to reduce the microbial infection and burden on these wounds, manage exudate secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from about 160 to 400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Additionally, exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation at the wound site and increase collagenase expression to debride necrotic tissue at the wound site. After a first treatment period with high concentration of nitric oxide, a second treatment period at a lower concentration of nitric oxide preferably ranging from about 5-20 ppm may to provided to restore the balance of nitric oxide and induce collagen expression to aid in the closure of the wound.
Owner:SENSORMEDICS +1
Target sequences for synthetic molecules
The invention is based on the discovery that certain biarsenical molecules react with specified target sequences, thereby providing a facile means for labeling polypeptides containing the target sequence. The invention is useful in creating stable mammalian cell lines expressing a certain tetracysteine tagged polypeptides, thereby overcoming toxicity associated with native tetracysteine. In addition, the invention allows for orthogonal labeling of polypeptides, thereby allowing for the observation of protein-protein interactions and conformational changes in proteins, for example.
Owner:LIFE TECH CORP
Compositions and methods for tumor-targeted delivery of effector molecules
InactiveUS20050249706A1Inhibit tumor growthReduce tumor volumeBiocideOrganic active ingredientsTumor targetAbnormal tissue growth
Owner:NANOTHERAPEUTICS INC
Conjugates with reduced adverse systemic effects
ActiveUS20050287155A1Modulate cell functionHybrid immunoglobulinsPeptide/protein ingredientsSide effectActive agent
A conjugate of an active agent and a targeting moiety having affinity for a target cell, in which the active agent has been modified by attachment of a cell membrane-impermeabilizing group so that, if the active agent so modified is cleaved from the conjugate in the blood plasma instead of inside the target cell, the cell membrane-impermeabilizing group prevents or limits entry of the modified active agent into cells, thus reducing its systemic or non-specific adverse effects, including toxicity.
Owner:KOSAN BIOSCI
Isolation of epithelial cells or their biochemical contents from excreta after in vivo isotopic labeling
The methods of the present invention allow for the non-invasive or minimally invasive isolation of epithelial cells or their biochemical contents from excreta after in vivo isotopic labeling. Once isolated, the labeled epithelial cells or their labeled biochemical contents find use as kinetic biomarkers of diseases of epithelial tissues including epithelial cancers and epithelial proliferative disorders such as psoriasis and benign prostate hyperplasia. The biomarkers are useful in diagnosing a disease of epithelial tissue origin, monitoring therapeutic efficacy of compounds or combinations of compounds used to treat diseases of epithelial tissue origin, screen new chemical entities or biological factors or combinations of chemical entities or biological factors, or mixtures thereof, for therapeutic activity in animal models of diseases of epithelial tissue origin or in human clinical trials, or test for toxicity on epithelial tissues from exposure to therapeutic compounds or new chemical entities or environmental chemicals such as industrial or occupational chemicals, environmental pollutants, food additives, and cosmetics.
Owner:RGT UNIV OF CALIFORNIA
Methods and compositions for labeling nucleic acids
The present invention relates to methods for the labeling of nucleic acid polymers in vitro and in vivo. Certain methods are provided that include a [3+2] cycloaddition between a nucleotide analogue incorporated into a nucleic acid polymer and a reagent attached to a label. Other methods are provided that include a Staudinger ligation between a nucleotide analogue incorporated into a nucleic acid polymer and a reagent comprising a substituted triarylphosphine attached to a label. Such methods do not require fixation and denaturation and therefore can be applied to the labeling of nucleic acid polymers in living cells and in organisms. Also provided are methods for measuring cellular proliferation. In these methods, the amount of label incorporated into the DNA is measured as an indication of cellular proliferation. The methods of the invention can be used in a wide variety of applications including clinical diagnosis of diseases and disorders in which cellular proliferation is involved, toxicity assays, and as a tool for the study of chromosomes' ultrastructures.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE +1
Antimicrobial food additive and treatment for cooked food, water and wastewater
A composition of matter with antimicrobial and antibacterial properties for treatment of water, wastewater, processed food and for use as a food additive is provided. The antimicrobial composition inhibits cellular growth of known pathogenic, indicator and spoilage organisms, such as salmonella, stahphylococcus, listeria, E-coli, aerobic and anerobic organisms in wastewater and the like. The antimicrobial composition of the present invention is useful in many situations and conditions in need of disinfectants and sanitizers. One of the primary benefits of the antimicrobial agent is that it inhibits the growth of bacteria that have become antibiotic resistant. In addition, the antimicrobial composition herein does not have any known toxicity to man or the environment.
Owner:TASKER PRODS IP HLDG CORP
Combinatorial interleukin-2 muteins
InactiveUS20060160187A1Maintaining and enhancing proliferationLower Level RequirementsPeptide/protein ingredientsTissue cultureNatural Killer Cell Inhibitory ReceptorsInterleukin II
Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins have lower toxicity than native IL-2 or Proleukin® IL-2, while maintaining or enhancing NK cell-mediated effects, and can be used in pharmaceutical compositions for use in treatment of cancer, and in stimulating the immune response.
Owner:CHIRON CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com